IPO Year: 2023
Exchange: NASDAQ
SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)
SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
EFFECT - MANGOCEUTICALS, INC. (0001938046) (Filer)
AW - MANGOCEUTICALS, INC. (0001938046) (Filer)
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
S-1 - MANGOCEUTICALS, INC. (0001938046) (Filer)
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)
POS AM - MANGOCEUTICALS, INC. (0001938046) (Filer)
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
Dallas, TX Based Men's Health Telemedicine Company Announces Successful Participation in Beijing ExhibitDALLAS, TX / ACCESSWIRE / August 8, 2024 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a leader in developing, marketing, and selling a variety of men's health and wellness products, is pleased to announce the receipt of its first Request for Proposal (RFP) from its distributor, the International Society of Frontier Life Sciences and Technology (ISFLST). This RFP focuses on the formulation, production, and packaging of a new male enhancement non-prescription product, intended to be introduced and sold in the Chinese market as a natural solution for men's health.This co
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial
Dallas, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that it has received a Certificate of Grant and recordal of patent under section 43 of the Patents Act in respect of patent application no. 202117034253 with the Government of India, originally applied for by Intramont Technologies, Inc. ("Intramont"). The duration of the patent granted in India is twenty (20) years from the effective filing date of
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, proudly announces the successful migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx's capabilities, reinforcing its commitment to innovation and superior patient care. The new operating system, authorized by the DEA and integrated with Surescripts, allows MangoRx's third-party doctor netw
Dallas, TX Based Men's Health Telemedicine Company Announces Successful Participation in Beijing ExhibitDALLAS, TX / ACCESSWIRE / August 8, 2024 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a leader in developing, marketing, and selling a variety of men's health and wellness products, is pleased to announce the receipt of its first Request for Proposal (RFP) from its distributor, the International Society of Frontier Life Sciences and Technology (ISFLST). This RFP focuses on the formulation, production, and packaging of a new male enhancement non-prescription product, intended to be introduced and sold in the Chinese market as a natural solution for men's health.This co
Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a leader in men's health and wellness products including erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce the initiation of efficacy studies on its patented respiratory illness prevention technology in collaboration with Vipragen Biosciences and IntraMont Technologies, Inc. Notably, these trials have been pre-funded, ensuring that the Company does not need to raise any additional capital for the completion of these studies, which are anticipated to be concluded in the earlier part of the 3rd quarter. The recently
DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that its CEO, Jacob Cohen, was recently featured on Benzinga All-Access. CLICK HERE TO WATCH THE COMPLETE INTERVIEW. In the interview with Zunaid Suleman, Cohen discussed Mangoceuticals' strategic direction, recent developments, expanding product offerings, and plans for global expansion. He emphasized the company's commitment to innovation
DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce obtaining DEA authorization for the company's groundbreaking HIPAA-compliant operating system through Surescripts. This significant milestone positions MangoRx at the forefront of the direct-to-consumer (DTC) telemedicine market. Securing DEA clearance to prescribe controlled medications via Surescripts, the nation's leading health information netwo
DALLAS, TEXAS, July 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that it has appointed Dr. Douglas Christianson, N.D. to serve as Director of the Medical Research and Product Innovation Department. Dr. Christianson will play an extensive and instrumental role in driving MangoRx's new product development initiatives. His responsibilities will encompass comprehensive market research and detailed analysis of innovati
DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce that it has secured a strategic partnership with the International Society of Frontier Life Sciences and Technology (ISFLST) for the distribution of its products in China and the Asia Pacific region and Latin America (excluding Mexico). This agreement marks a significant milestone in MangoRx's expansion strategy, aiming to bring its premier men's heal
Studies Pre-Funded, No Additional Capital Needed; Expected Completion Early Q3 2024
Shares of Stitch Fix, Inc. (NASDAQ:SFIX) rose sharply in today's pre-market trading following better-than-expected third-quarter financial results. Stitch Fix reported quarterly losses of 18 cents per share which beat the analyst consensus estimate of losses of 24 cents by 25%. Quarterly sales came in at $322.7 million which beat the analyst consensus estimate of $306.121 million by 5.42% and represents a 18.29% decrease in sales from the same period last year, according to data from Benzinga Pro. Stitch Fix shares jumped 18% to $3.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) rose 7
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that it has received a Notice of Allowance for Japanese Patent Application No. 2021-545824, originally applied for by Intramont Technologies, Inc. ("Intramont").This significant milestone follows MangoRx's recent acquisition of the comprehensive global patent portfolio from Intramont Technologies. The Notice of Allowance covers the proprietary formulation and application methods designed to combat a wid
MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT)Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone and Dehydroepiandrosterone (DHEA) in an Oral Dissolvable Tablet (ODT) aimed at restoring hormonal balance and naturall